Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | DNA polymerase eta, putative | 0.0037 | 0.5597 | 0.4775 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0037 | 0.5597 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0037 | 0.5597 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1847 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0053 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0053 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0053 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0053 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Echinococcus multilocularis | dna polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Schistosoma mansoni | DNA polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.9701 | 0.9633 |
Leishmania major | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0052 | 0.9701 | 0.9633 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1847 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 13 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.